Clinical trials: Affective Disorders
Depression, Depressive Disorder
Mindful Breathing and tDCS for Depression
This study will investigate whether transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC) can enhance the therapeutic effect of mindful breathing training (MBT) for adolescent…
- Trial name
- NCT03897699
- Testing
- Transcranial Direct Current Stimulation, Mindful Breathing
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Minnesota
Metabolic Syndrome, Bipolar Depression
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance.
- Conditions
- Metabolic Syndrome, Bipolar Depression, Insulin Resistance
- Trial name
- NCT00835120
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University Hospitals Cleveland Medical Center
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders
Children between the ages of 5-17 years old who have or display symptoms of emotional dysregulation (explosiveness, mood swings, irritability, and/or violent behavior) are invited to participate in a 12-week research study to…
- Trial name
- NCT02357290
- Testing
- Open-label Treatment with N-Acetylcysteine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Insulin Resistance
Pioglitazone for the Treatment of Bipolar Depression
The primary objective is to test the hypothesis that adjunctive pioglitazone is more effective than placebo for the relief of acute depressive symptoms resulting from bipolar disorder.
- Trial name
- NCT01717040
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University Hospitals Cleveland Medical Center
Tobacco Use Disorder
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions.
- Trial name
- NCT04090879
- Testing
- Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g), E-Cigarettes
- Where
- 2 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Brown University
Bipolar Disorder
NMDA Antagonists in Bipolar Depression
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression.
- Trial name
- NCT01833897
- Testing
- Standard of Care, Ketamine, D-cycloserine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
- Trial name
- NCT03188185
- Testing
- ALKS 5461
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 278 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder, Healthy Controls
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs.
- Trial name
- UNIKET (NCT05046184)
- Testing
- Ketamine Hydrochloride, Midazolam injection
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Brain Imaging Techniques That Predict Antidepressant Responsiveness
Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine treatment and do changes in selective structures, such as the amygdala, predict treatment response?
- Trial name
- WyethKolden (NCT00909155)
- Testing
- Venlafaxine ERT, Fluoxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Depressive Disorder, Major
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
- Trial name
- NCT00186498
- Testing
- memantine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Depression, Postpartum, Anxiety
Preventing Postpartum Depression With Intranasal Oxytocin
The purpose of this study is to test a new treatment for preventing childbirth-related mental illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety…
- Trial name
- IN-OXT (NCT02505984)
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Decision-Making in Bipolar Disorder
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study.
- Trial name
- NCT01463111
- Testing
- Lithium, Valproate, Lamotrigine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Emory University
Major Depressive Disorder
A Study of LY2216684 and Theophylline in Healthy Subjects
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme.
- Trial name
- NCT01263106
- Testing
- LY2216684, Theophylline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder…
- Trial name
- NCT02943564
- Testing
- Rapastinel
- Where
- 66 sites in United States
- Volunteers
- 658 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Major Depression
Brain Imaging of Quetiapine Response in Anxious Depression
The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients.
- Trial name
- NCT00982345
- Testing
- quetiapine (Seroquel XR)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Bipolar Disorder, Weight Gain
Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
The primary objective of this study is to examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.
- Trial name
- NCT00394095
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Cincinnati